BrainChild Bio Raises $116M Series A to Fund Phase 2 ILLUMINATE Trial of BCB‑276 for DIPG

BrainChild Bio, a Seattle clinical-stage biotech led by CEO Steven Brugger, raised $116M in a Series A led by an undisclosed private family fund and foundation with participation from Seattle Children’s and WRF Capital to fund Phase 2 ILLUMINATE study of BCB‑276 for DIPG and continued development of BCB‑214 for glioblastoma.

SSteven Brugger BBrainChild Bio SSeattle Children's Hospital